Donald K. Strickland

Author

Also Known As

D K Strickland, D Strickland, D. Strickland, D.K. Strickland, Donald K Strickland, Donald K. Strickland, Donald Strickland

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center The University of Texas MD Anderson Cancer Center Sarah Cannon Tennessee Oncology Washington University in St. Louis

About

Donald K. Strickland is an author at Duke Medical Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	848
2	Health Sciences	1	1	56
3	Cell Biology	1	1	54
4	Emergency Medicine	1	1	70
5	Hepatology	1	1	56

Donald K. Strickland

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, The Lancet Oncology Dll3-targeted Antibody-drug ConjugateMedicineImmunologyImmune Checkpoint InhibitorCancer Treatment	2016	537
Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia Wing Leung, Melissa M. Hudson, Donald K. Strickland, Journal of Clinical Oncology	2000	210
The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort Sharon M. Castellino, Shelly Lensing, Caroline A. Riely, Blood	2003	95
Hepatitis C infection among survivors of childhood cancer Donald K. Strickland, Caroline A. Riely, Christian C. Patrick, Blood	2000	86
Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Steven Arkin, Francine Blei, James Fetten, PubMed Novoseven Emergency-use ProgrammeBleeding EpisodesEmergency-use StudyThrombosisHematology	2000	70
Hepatitis C Infection and Hepatocellular Carcinoma After Treatment of Childhood Cancer Donald K. Strickland, Jesse J. Jenkins, Melissa M. Hudson The American journal of pediatric hematology/oncology ImmunologyPathologyChildhood Cancer SurvivorsImmunotherapyCirrhosis	2001	56
Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells. Donald K. Strickland, G Vaidyanathan, Michael R. Zalutsky PubMed Mibg AnaloguePharmacotherapyGliomaTumor BiologyNeuro-oncology	1994	54
<i>Meta</i>‐[<sup>211</sup>AT]astatobenzylguanidine: Further evaluation of a potential therapeutic agent G Vaidyanathan, Donald K. Strickland, Michael R. Zalutsky International Journal of Cancer	1994	35
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours Melissa L. Johnson, Judy S. Wang, Gerald S. Falchook, British Journal of Cancer	2023	33
Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, Journal of Clinical Oncology Dll3 HiImmunologyPathologyPharmacotherapyHematological Malignancy	2016	24

Page 1